Nicole A. Colwell, MD

For many community sites, the question is not whether to offer BsAbs but how to implement them safely and sustainably. Recognizing these needs, ACCC developed 2 practical, implementation-focused tools to support programs at every stage of readiness.

ACCC is excited to share its new provider resources for TIL cell therapy, including a referral readiness checklist, patient pathway guide, and white paper with tangible steps for improving access.

The JADPRO Live 2025 conference convened thousands of APPs in hematology and oncology for 4 days of clinical education, collaboration, and professional growth.

To help teams navigate treatment decisions for Relapsed/refractory (R/R) follicular lymphoma (FL), ACCC developed an Effective Practice Guide (EPG) that focuses on practical strategies for delivering high-quality care. 

Despite the best intentions of their providers, patients and caregivers often report feeling uncertain, unsupported, or overwhelmed during treatment selection for CLL—an important part of the patient journey.

Fueled by advances in digital health technology and the growing need to address operational constraints in nonacademic settings, decentralized clinical trial designs are poised to redefine how (and where) clinical evidence is generated.

As we recognize National Cancer Research Month this May, it's important to acknowledge the continued need to strengthen the clinical trial workforce and to explore solutions that can expand access to potentially lifesaving clinical trials.

As we observe World Ovarian Cancer Day in 2025, health care professionals are encouraged to recognize how precision oncology is reshaping treatment paradigms and presenting new opportunities to personalize care and improve survival outcomes.

While ADCs have emerged as a promising development for patients with NSCLC, they present unique challenges in clinical practice, such as optimal patient selection, treatment sequencing, and toxicity management. ADCs can also elicit significant adverse events, particularly when combined with immunotherapy, raising concerns about overlapping toxicities and the need for close monitoring for treatment-related complications.

By leveraging machine learning algorithms, natural language processing, and data analytics, AI accelerates the identification of potential drug candidates, optimizes preclinical and clinical testing, and reduces costs.

Chronic inflammation, a driving force behind tumor initiation and progression, is central to understanding the biology of cancer, as is the concept of inflammaging—the chronic, low-grade inflammation associated with aging.

Despite substantial advances in screening, diagnosis, and treatment, notable disparities exist in oncology that often result in delayed diagnoses, suboptimal treatment, poor outcomes, and undertreatment of pain in certain racial and ethnic groups.

By leveraging modern health care technologies and data-driven insights, AI and machine learning have the potential to enhance screening, diagnosis, and personalized treatment strategies across multiple cancer types.

In an attempt to enhance patient access, comfort, and convenience while achieving institutional cost savings, the Froedtert & Medical College of Wisconsin Blood and Marrow Transplant and Cellular Therapy Program expanded its offerings by introducing autologous transplants as an outpatient service.

One of the most important things that health care providers can do for patients with non-melanoma skin cancer is coordinate treatment. Multidisciplinary teams in non-melanoma skin cancer care can help determine the best care plan for each patient and improve the quality of care.

Since 2022, the introduction of 6 additional T cell–engaging bispecific antibodies has transformed the therapeutic landscape across several oncologic, hematologic, and ophthalmologic indications. These approvals catalyzed a need for institutions to develop operational processes that would ensure safe and effective delivery of these novel therapeutics.

In a noteworthy quality improvement initiative, Advocate Health and Hospitals Corporation/Advocate Medical Group in Illinois has achieved a regional Quality Oncology Practice Initiative (QOPI®) certification.

Lung cancer remains the leading cause of cancer-related death in the United States, accounting for more fatalities than colorectal and pancreatic cancer combined. One of the keys to improving clinical outcomes lies in early detection and intervention, especially for incidental lung nodules, which could be an early indicator of lung cancer.